Previously submitted to: JMIR Cancer (no longer under consideration since Dec 13, 2023)
Date Submitted: Mar 21, 2023
Open Peer Review Period: Mar 21, 2023 - May 16, 2023
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Continued Use of Telehealth In Oncology Patients
ABSTRACT
Background:
Prior to the Covid-19 pandemic, telehealth represented a small portion of our oncology practice. Despite offering telehealth availability, fewer than 10% of patients agreed to virtual visits. Administratively, there were concerns about patients’ ability to use the technology, a change in the traditional in office dynamic, questions about whether patients would consistently use these platforms, etc. At the height of the pandemic, as much as 30% of our practice became fully telehealth. As the height of the pandemic has waned, we continue to offer telehealth for both new and establishing patients. We opted to retrospectively look at the continued use of telehealth in our practice.
Objective:
Our objective was to determine if patients who did an initial telehealth visit would request future telehealth visits or if they would opt to return to the traditional in office model. Patients treated in 2022 were offered repeat telehealth visits or in person visits by the scheduling staff after their visit. The offer was presented without offering any bias toward future visit.
Methods:
25% of our practice has dedicated telehealth slots. Of patients who opted for a telehealth visit, we followed future visits to determine if they opted to continue use of telehealth technology. We also looked at the age of the patient and the diagnosis of the patient to look for trends.
Results:
With a retrospective review of 99 charts, we separated patients into new visits to the cancer center vs patients who were already established. Of the 23 new patient visits, 14 were for a new diagnosis of solid tumor oncology and nine had a hematologic diagnosis. The average age of these patients was 55 (32-80). 13/21 (62%) who had repeat visits did so virtually. Of 76 patients who were already established, 43 had a hematologic diagnosis, 33 a solid tumor diagnosis. The average age was 61 (21-88). 55/76 (72%) opted for repeat telehealth visits. No clear trends in terms of age or diagnosis emerged in terms of who accepted repeat telehealth visits.
Conclusions:
For patients who had an initial telehealth visit, it was likely they would continue to use this technology. Concerns about the age of patient or type of diagnosis did not preclude continued use of telehealth. This supports the continued use of telehealth in the post pandemic setting. Clinical Trial: None
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.